- Home
- ABTS vs NKGN Comparison
ABTS vs NKGN Comparison
Compare ABTS & NKGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- NKGN
- Stock Information
- Founded
- ABTS 2010
- NKGN 2017
- Country
- ABTS Hong Kong
- NKGN United States
- Employees
- ABTS N/A
- NKGN N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- NKGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABTS Technology
- NKGN Health Care
- Exchange
- ABTS Nasdaq
- NKGN Nasdaq
- Market Cap
- ABTS 16.0M
- NKGN 14.1M
- IPO Year
- ABTS N/A
- NKGN N/A
- Fundamental
- Price
- ABTS $0.46
- NKGN $0.65
- Analyst Decision
- ABTS
- NKGN
- Analyst Count
- ABTS 0
- NKGN 0
- Target Price
- ABTS N/A
- NKGN N/A
- AVG Volume (30 Days)
- ABTS 88.2K
- NKGN 570.0K
- Earning Date
- ABTS 12-31-2024
- NKGN 12-24-2024
- Dividend Yield
- ABTS N/A
- NKGN N/A
- EPS Growth
- ABTS N/A
- NKGN N/A
- EPS
- ABTS N/A
- NKGN N/A
- Revenue
- ABTS $5,343,888.00
- NKGN N/A
- Revenue This Year
- ABTS N/A
- NKGN N/A
- Revenue Next Year
- ABTS N/A
- NKGN N/A
- P/E Ratio
- ABTS N/A
- NKGN N/A
- Revenue Growth
- ABTS 3970.67
- NKGN N/A
- 52 Week Low
- ABTS $0.38
- NKGN $0.20
- 52 Week High
- ABTS $1.60
- NKGN $4.06
- Technical
- Relative Strength Index (RSI)
- ABTS 40.47
- NKGN 65.93
- Support Level
- ABTS $0.41
- NKGN $0.45
- Resistance Level
- ABTS $0.58
- NKGN $0.62
- Average True Range (ATR)
- ABTS 0.07
- NKGN 0.08
- MACD
- ABTS -0.02
- NKGN 0.01
- Stochastic Oscillator
- ABTS 14.52
- NKGN 70.95
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations.
About NKGN NKGen Biotech Inc.
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.